 EMERYVILLE, Calif., Aug. 20, 2021 PRNewswire -- Amyris, Inc. Nasdaq: AMRS, a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute IDRI. 